You just read:

Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting

News provided by

Cirius Therapeutics

Nov 08, 2019, 08:00 ET